CONVERT PHARMACEUTICALS
ActiveSummary
The computed 12-month bankruptcy probability of CONVERT PHARMACEUTICALS is 1.9% (moderate). The 2025 annual accounts show negative equity (-€841,823) and a net result of -€629,343. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 5% of 240 sector peers (NACE 72, financial year 2025). The company has been active since 2017 and the Belgian Official Gazette contains no insolvency or warning signals.
Articles of association
- Other provisionsOther rules from the articles that fall under none of the themes above.
- Other provision: “Responsabilité de l’organe d’administration relative à l’apport en nature, organe d’administration” (deed in French)Other provision: “Responsabilité de l’organe d’administration relative à l’émission d’actions, organe d’administration” (deed in French)Other provision: “Responsabilité du réviseur d’entreprises relative à l’apport en nature, réviseur d’entreprises” (deed in French)Other provision: “Données comptables et financières contenues dans le rapport spécial de l’organe d’administration, responsabilité du réviseur d’entreprises…” (deed in French)
Read from the deeds: 4 provisions, deed of 07-07-2025